Accepted Manuscript



Title: Conditioning Regimen with Plerixafor is Safe and Improves the Outcome of TCRαβ+ and CD19+ Cell–Depleted Stem Cell Transplantation in Wiskott–Aldrich Syndrome Patients

Author: Dmitry Balashov, Alexandra Laberko, Anna Shcherbina, Pavel Trakhtman, Dmitrii Abramov, Elena Gutovskaya, Svetlana Kozlovskaya, Larisa Shelikhova, Galina Novichkova, Michael Maschan, Alexander Rumiantsev, Alexei Maschan

PII: S1083-8791(18)30119-8
DOI: https://doi.org/10.1016/j.bbmt.2018.03.006
Reference: YBBMT 55060

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 16-1-2018
Accepted date: 7-3-2018

Please cite this article as: Dmitry Balashov, Alexandra Laberko, Anna Shcherbina, Pavel Trakhtman, Dmitrii Abramov, Elena Gutovskaya, Svetlana Kozlovskaya, Larisa Shelikhova, Galina Novichkova, Michael Maschan, Alexander Rumiantsev, Alexei Maschan, Conditioning Regimen with Plerixafor is Safe and Improves the Outcome of TCRαβ+ and CD19+ Cell–Depleted Stem Cell Transplantation in Wiskott–Aldrich Syndrome Patients, *Biology of Blood and Marrow Transplantation* (2018), https://doi.org/10.1016/j.bbmt.2018.03.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Title page

Title: Conditioning regimen with plerixafor is safe and improves the outcome of TCRαβ+ and CD19+ cell-depleted stem cell transplantation in Wiskott-Aldrich syndrome patients

Authors:
Dmitry Balashov MD[1]; Alexandra Laberko MD[2]; Anna Shcherbina MD, PhD[2]; Pavel Trakhtman MD[4]; Dmitrii Abramov MD[3]; Elena Gutovskaya MD[1]; Svetlana Kozlovskaya MD[1]; Larisa Shelikhova MD[1]; Galina Novichkova MD[5]; Michael Maschan MD[1]; Alexander Rumiantsev MD, PhD[5] and Alexei Maschan MD, PhD[1]

[1] Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
[2] Department of Immunology, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
[3] Department of Pathology, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
[4] Transfusion Medicine Service, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
[5] Medical Department, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Corresponding author

Dmitry Balashov, MD, bala8@yandex.ru

phone: +7 926 5791817

Department of hematopoietic stem cell transplantation,

Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology Postal address: 1, Samory Mashela str., 117997, Moscow, Russia

Short title: Plerixafor for TCRαβ+ depleted SCT in WAS patients

Highlights

- Mixed chimerism was not observed after HSCT with G-CSF/plerixafor in conditioning
- Risk of graft dysfunction decreased after conditioning with G-CSF/plerixafor
- There was no difference in outcomes after MUD/haploidentical TCRαβ+depleted HSCT

Abstract

Our initial experience of hematopoietic stem cell transplantation (HSCT) from a matched unrelated donor (MUD; n=12) or a haploidentical related donor (n=6) with TCRαβ+/CD19+ graft depletion for Wiskott-Aldrich syndrome (WAS) patients (n=18) showed a dramatic decrease in the incidence of graft-versus-host disease (GVHD) and transplant-related

Accepted Manuscript

Download English Version:

https://daneshyari.com/en/article/8429727

Download Persian Version:

https://daneshyari.com/article/8429727

Daneshyari.com